Esperion Therapeutics (ESPR) Gross Margin: 2020-2025
Historic Gross Margin for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to 52.71%.
- Esperion Therapeutics' Gross Margin fell 1381.00% to 52.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 58.20%, marking a year-over-year decrease of 2338.00%. This contributed to the annual value of 79.36% for FY2024, which is 1655.00% up from last year.
- Latest data reveals that Esperion Therapeutics reported Gross Margin of 52.71% as of Q3 2025, which was down 19.35% from 65.35% recorded in Q2 2025.
- Esperion Therapeutics' 5-year Gross Margin high stood at 95.57% for Q2 2021, and its period low was 51.30% during Q2 2022.
- In the last 3 years, Esperion Therapeutics' Gross Margin had a median value of 64.49% in 2023 and averaged 65.58%.
- As far as peak fluctuations go, Esperion Therapeutics' Gross Margin plummeted by 4,428bps in 2022, and later spiked by 4,058bps in 2024.
- Quarterly analysis of 5 years shows Esperion Therapeutics' Gross Margin stood at 67.05% in 2021, then skyrocketed by 1,085bps to 77.89% in 2022, then crashed by 1,340bps to 64.49% in 2023, then plummeted by 158bps to 62.91% in 2024, then plummeted by 1,381bps to 52.71% in 2025.
- Its Gross Margin stands at 52.71% for Q3 2025, versus 65.35% for Q2 2025 and 51.48% for Q1 2025.